A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy nd safety: Imbalanced sample size in treatment groups

Statistical Methods in Medical Research

Volumn 20, Issue 4, 2011, Pages 389-400

  Kikuchi, Takashi ^a   Gittins, John ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BAYES THEOREM; COST BENEFIT ANALYSIS; EVIDENCE BASED PRACTICE; LOGISTIC REGRESSION ANALYSIS; MONTE CARLO METHOD; SAMPLE SIZE;

BAYES THEOREM; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; DECISION THEORY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MONTE CARLO METHOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 80051867134     PISSN: 09622802     EISSN: 14770334     Source Type: Journal    
DOI: 10.1177/0962280209358131     Document Type: Article

References (27)

1. Gittins JC, Pezeshk H. A behavioral Bayes method for determining the size of a clinical trial. Drug Information Journal 2000; 34: 355-63. (Pubitemid 30350988)
2. Gittins JC, Pezeshk H. How Large should a clinical trial be? The Statistician 2000; 49(2): 177-87.
3. Gittins JC, Pezeshk H. A decision theoretic approach to sample size determination in clinical trials. Journal of Biopharmaceutical Statistics 2002; 12(4): 535-51. (Pubitemid 35439798)
4. Gittins JC, Pezeshk H. A fully Bayesian approach to calculating sample sizes for clinical trials with binary responses. Drug Information Journal 2002; 36: 143-50. (Pubitemid 34208210)
5. Kikuchi T, Pezeshk H, Gittins J. A Bayesian cost-benefit approach to the determination of sample size in clinical trials. Statistics in Medicine 2008; 27(1): 68-82. (Pubitemid 351193660)
6. Kikuchi T, Gittins J. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety. Statisticsin Medicine2009;28(18):2293-306.
7. Brutti P, De Santis F, Gubbiotti S. Robust Bayesian sample size determination in clinical trials. Statistics in Medicine 2008; 27: 2290-306. (Pubitemid 351802895)
8. Spiegelhalter DJ, Freedman LS. A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. Statistics in Medicine 1986; 5: 1-13. (Pubitemid 16132211)
9. Hutton JL, Owens RG. Bayesian sample size calculation and prior beliefs about child sexual abuse. The Statistician 1993; 42: 399-404.
10. Joseph L, du Berger R, Belisle P. Bayesian and mixed Bayesian likelihood criteria for sample size determination. Statistics in Medicine 1997; 16: 769-81. (Pubitemid 27165682)
11. Lee SJ, Zelen M. Clinical trials and sample size considerations: another perspective. Statistical Science 2000; 15: 95-103.
12. Willan AR. Optimal sample size determinations from an industry perspective based on the expected value of information. Clinical Trials 2008; 5: 587-94.
13. Claxton K, Posnett J. An Economic approach to clinical trial design and research priority-setting. Health Economics 1996; 5: 513-24.
14. Patel NR, Ankolekar S. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drug and portfolios of drugs. Statistics in Medicine 2007; 26: 4976-988. (Pubitemid 350064917)
15. Dumville JC, Hahn S, Torgerson DJ. The use of unequal randomisation ratios in clinical trials: A review. Contemporary Clinical Trials 2006; 27: 1-12. (Pubitemid 41758434)
16. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, 1: introduction and design. British Journal of Cancer 1976; 34: 585-612. (Pubitemid 8004970)
17. Peto R. Clinical trial methodology. Biomedicine 1978; 28: 24-36. (Pubitemid 9017348)
18. Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics 1979; 35: 183-97. (Pubitemid 9136574)
19. Bernardo JM, Smith AFM. Bayesian Theory (Wiley Series in Probability and Statistics). Wiley Chichester; 1994.
20. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. The American Journal of Medicine 2001; 111: 185-91. (Pubitemid 32786945)
21. Schwartz GG, Bolognese MA, Tremblay BP, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholes-terolemia and a high riskof coronary heart disease: A randomized, controlled trial. American Heart Journal 2004; 148(1): 105-13.
22. Expert Panel on Detection, Evaluation and TreatmentofHighBloodCholesterolinAdults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Vol. 106; 2002.
23. Liu JLY, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002; 88: 597-603. (Pubitemid 35418074)
24. Samuelson W, Zeckhauser R. Status quo bias in decision making. Journal of Risk and Uncertainty 1988; 1: 7-59
25. Clinical operations: accelerating trials, allocating resources and measuring performance; 2006. Available at http://www.ClinicalTrialBenchmarking. com (accessed 1 September 2006).
26. Bazalo GR. Managed care trends in statin usage. Managed Care 2001; 10(10): 48-59.
27. Dobson AJ. Calculating sample size. Trans Menzies Foundation 1984; 7: 75-9.